Divya Yerramilli, MD, MBE, Alexandra Charrow, MD, MBE, and Arthur Caplan, PhD
Physicians should be aware of the powerful impact celebrities’ cancer narratives can have on patients’ experiences of their illnesses and treatment decisions. Partnering with celebrities is one strategy for delivering evidence-based health information and messaging to the public.
AMA J Ethics. 2018;20(11):E1075-1081. doi:
10.1001/amajethics.2018.1075.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Rebekah Davis Reed, PhD, JD and Erik L. Antonsen, PhD, MD
Though the National Aeronautics and Space Administration’s collection of disaggregated genetic data for occupational surveillance and research raises numerous privacy concerns, the Genetic Information Nondiscrimination Act of 2008 allows genetic information to be used to develop personal pharmaceuticals.
AMA J Ethics. 2018;20(9):E849-856. doi:
10.1001/amajethics.2018.849.